[Geneva, Switzerland – December 9, 2010]
The Geneva-based organizations Drugs for Neglected Diseases initiative (DNDi), Foundation for Innovative New Diagnostics (FIND), and Medicines for Malaria Venture (MMV) have been recognized as “other International Organizations” by the Swiss Government with effect from the first of January 2011. This represents an important recognition of their goals to drive the development and implementation of effective, low-cost and innovative drugs and diagnostic tests to fight diseases that affect millions of people in the world’s poorer regions.
[Geneva, Switzerland – December 9, 2010]
[New Delhi, India – December 3, 2010]
Over 150 Indian and international health researchers, policy makers, experts from 22 countries met on December 3rd, at the Constitutional Club in New Delhi for the 3rd International Partners meeting organized by Drugs for Neglected Diseases initiative (DNDi) in collaboration with Indian Council for Medical Research (ICMR) to stimulate greater regional research partnership to fight the most neglected diseases such as Kala-azar sleeping sickness, malaria and Chagas disease.
[Geneva, Switzerland – December 3, 2010]
The Ministry of Foreign Affairs of the Netherlands has granted 14 million Euros to the Drugs for Neglected Diseases initiative (DNDi) to fight neglected tropical diseases. The grant will be disbursed over four years (2011-2014) and will provide critical funding for DNDi on the core disease programmes for human African trypanosomiasis, Chagas disease, and leishmaniasis. This is the second time that the Dutch government has awarded funding to DNDi.
[PRESS RELEASE FROM NATURE PUBLISHING GROUP – July 22, 2010]
Nature Publishing Group (NPG) and InnoCentive, the world leader in open innovation, today announced that Solver Sandip Bharate has been awarded $10,000 for his solution to a Challenge posted on the nature.com open innovation pavilion (www.nature.com/openinnovation) by Drugs for Neglected Diseases initiative (DNDi) in January of this year. Solver Bharate is a Postdoctoral Scientist in Biomedical and Pharmaceutical Science from Missoula, Montana.
[New York, United States and Geneva, Switzerland – July 7, 2010]
A Unique Collaboration: TB Alliance and DNDi Enter Cross-Disease License Agreement to Speed Development of Novel Therapies
The Global Alliance for TB Drug Development (TB Alliance) and Drugs for Neglected Diseases initiative (DNDi) announced today a unique first-ever royalty-free license agreement between two not-for-profit drug developers that speeds progress toward markedly improved therapy of multiple neglected diseases. The TB Alliance has granted rights to DNDi to develop a class of potential anti-TB compounds that also show significant promise for treating other neglected diseases that largely affect the world’s poor. This agreement highlights the efficiency and synergy of product development partnerships (PDPs), and how investment in PDPs is producing a robust and diverse pipeline of tools to treat a wide variety of neglected diseases.
[Geneva, Switzerland – May 17, 2010]
The Resolution ‘Chagas Disease: Control and Elimination’ to be adopted by the WHO is a step in the right direction but lacks essential elements
At the ‘World Health Assembly’ (May 17-22, 2010) in Geneva, the resolution ‘Chagas Disease: Control and Elimination’ is about to be adopted by the World Health Organization (WHO). Although this is a step in the right direction, the resolution lacks essential elements. Médecins Sans Frontières/Doctors Without Borders (MSF) and Drugs for Neglected Disease initiative (DNDi) call on WHO Member States to include in the resolution the integration of treatment and diagnosis at the primary healthcare level and increased efforts in research and development.
[New York, USA – March 30, 2010]
Thirteen members of Congress are formally urging US AID to expand R&D funding for treatments for four deadly tropical diseases that impact millions of people in developing countries, yet are largely left out of the Obama Administration’s new Global Health Initiative. The impassioned request was made in a letter sent to Dr. Rajiv Shah, Administrator of the US Agency for International Development, and is fully in step with the goals of the Drugs for Neglected Diseases initiative.
[Berlin, Germany – March 23, 2010]
Médecins Sans Frontiéres Germany, the German Foundation for World Population (DSW) and the Church Development Service (Evangelischer Entwicklungsdienst – EED) are calling the German government and the Federal Ministry of Education and Research to invest more in research for poverty-related neglected diseases. Tomorrow, March 24, on the World Tuberculosis Day, the three NGOs will debate with policy, research and civil society experts possible solutions and innovative models to close the existing research gap at a public conference called “Poverty related neglected diseases – new models for promoting research”.
[Geneva, Switzerland/Barcelona, Spain – March 15, 2010]
Today, Drugs for Neglected Diseases initiative, the Barcelona Centre for International Health Research and the Clinic Foundation for Biomedical Research signed an agreement to join forces on clinical research on Chagas disease. Dr. Bernard Pècoul, Executive Director of the Drugs for Neglected Diseases initiative (DNDi), Dr. Pedro L. Alonso, Director of the Barcelona Centre International Health Research (CRESIB)/Hospital Clínic-Barcelona University, and Mr. Emili Bargalló, Director of the Clinic Foundation for Biomedical Research (FCRB), signed the agreement, which will allow enhancing and maximizing resources and efforts in clinical research for Chagas diseases, with the ultimate goal to improve and obtain effective treatments.
[London, UK – March 10, 2010]
Recognising Excellence in Health Care
The annual BMJ Group Awards recognises individuals, organisations, and initiatives that have demonstrated outstanding and measurable contributions to health care. An article on malaria published in The Lancet received the Award of Research Paper of the Year. Among the authors are a DNDi Senior Project Manager (Isabela Ribeiro), a DNDi Board member (Prof. Abul Faiz), WHO/TDR researchers, and investigators from several countries.
[New York, USA – February 24, 2010]
Funding Needed to Combat Most Deadly Neglected Diseases
The Obama administration’s Global Health Initiative (GHI) does not go far enough in combating the most lethal neglected tropical diseases for which an estimated one billion people are infected, the international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) and the Drugs for Neglected Diseases initiative (DNDi) said today.
[Geneva, Switzerland/ Pretoria, South Africa – February 19, 2010]
A report commissioned by DNDi assesses pathway to facilitate review of new neglected diseases’ drugs by African experts
Today, at the ‘Council on Health Research for Development’ (COHRED) and ‘The New Partnership for Africa’s Development’ (NEPAD) meeting in Pretoria, South Africa, the Drugs for Neglected Diseases initiative (DNDi) and the George Institute for International Health release the report “Registering New Drugs: the African Context”. The report issues new recommendations to strengthen regulatory authorisation processes in Africa for drugs against neglected diseases.
[London/Geneva – January 29, 2010]
Infectious diseases that affect 30 million people worldwide are the focus of a new Challenge posted today on the nature.com Open Innovation Pavilion (www.nature.com/openinnovation). The Drugs for Neglected Diseases initiative (DNDi) is looking for potential targets for drugs against African Sleeping Sickness, Visceral Leishmaniasis, Cutaneous Leishmaniasis, and Chagas Disease.